Liontos Michalis, Terpos Evangelos, Markellos Christos, Zagouri Flora, Briasoulis Alexandros, Katsiana Ioanna, Skafida Efthymia, Fiste Oraianthi, Kunadis Elena, Andrikopoulou Angeliki, Kaparelou Maria, Koutsoukos Konstantinos, Gavriatopoulou Maria, Kastritis Efstathios, Trougakos Ioannis P, Dimopoulos Meletios-Athanasios
Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Vaccines (Basel). 2021 Oct 8;9(10):1148. doi: 10.3390/vaccines9101148.
Vaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, limited data exist for cancer patients under systemic therapy.
In this cohort, we prospectively enrolled cancer patients treated with PARPi as well as healthy volunteers in order to study the kinetics of anti-SARS-CoV-2 antibodies (NAbs) after COVID-19 vaccination. Baseline demographics, co-morbidities, and NAb levels were compared between the two groups.
The results of the cohort of 36 patients receiving PARP inhibitors are presented here. Despite no new safety issues being noticed, their levels of SARS-CoV-2 neutralizing antibodies were significantly lower in comparison to matched healthy volunteers up to day 30 after the second dose.
These results suggest that maintaining precautions against COVID-19 is essential for cancer patients and should be taken into consideration for the patients under treatment, while further exploration is needed to reduce the uncertainty of SARS-CoV-2 immunity among cancer patients under treatment.
接种新型冠状病毒2（SARS-CoV-2）疫苗可为普通人群提供针对该感染的显著保护。然而，关于接受全身治疗的癌症患者的数据有限。
在本队列研究中，我们前瞻性纳入了接受聚（ADP-核糖）聚合酶抑制剂（PARPi）治疗的癌症患者以及健康志愿者，以研究新型冠状病毒肺炎（COVID-19）疫苗接种后抗SARS-CoV-2抗体（NAbs）的动力学。比较了两组的基线人口统计学特征、合并症和NAb水平。
本文展示了36例接受PARP抑制剂治疗患者的队列研究结果。尽管未发现新的安全问题，但在第二剂接种后30天内，与匹配的健康志愿者相比，他们的SARS-CoV-2中和抗体水平显著较低。
这些结果表明，对癌症患者而言，维持针对COVID-19的预防措施至关重要，对于正在接受治疗的患者应予以考虑，同时需要进一步探索以降低正在接受治疗的癌症患者中SARS-CoV-2免疫的不确定性。
